Treatment of thalassemia-induced osteoporosis with pamidronate

Effect of low dose pamidronate in the treatment of thalassemia-induced osteoporosis

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211008052698N1

Enrollment

Registered

2021-10-29

Start date

2021-08-16

Completion date

Unknown

Last updated

2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thalassemia. Beta thalassemia

Interventions

Intervention group: Pamidronate , intravenously in the monthly dosages of 1 mg/kg over six month.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Z-score 1000 mg/dl More than 10 blood infusions or More than 100 cc/kg of blood infusion per year Normal creatinine level Normal blood counts

Exclusion criteria

Exclusion criteria: The positive history of bone-related disorders Leukemia or Neoplastic disorders Gastrointestinal disorders Chronic inflammatory diseases

Design outcomes

Primary

Measure	Time frame
Bone mineral densitometry. Timepoint: Baseline , Six month later. Method of measurement: Dual X-Ray absorptiometry.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarid Ghazizadeh

Oroumia University of Medical Sciences

ghazizadeh.f@umsu.ac.ir+98 44 3224 1967

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026